Latest Tonix Pharm Hldg Cor (TNXP) Headlines Toni
Post# of 112
Posted On: 03/11/2014 8:18:26 PM
Latest Tonix Pharm Hldg Cor (TNXP) Headlines
Tonix Pharmaceuticals to Present at the ROTH Conference
GlobeNewswire - Wed Mar 05, 7:20AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a development stage specialty pharmaceutical company, will be presenting at the 26 Annual ROTH Conference in Laguna Niguel, California. Seth Lederman, M.D., president and CEO of Tonix, will deliver a corporate overview on Tuesday, March 11, 2014 at 12:30 PM PT.
Tonix Pharmaceuticals Completes Pre-IND Meeting With FDA on TNX-201 for Episodic Tension-Type Headache: Clinical Development to Begin in 4Q 2014
GlobeNewswire - Mon Mar 03, 8:35AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a development stage specialty pharmaceutical company, today announced that it recently held a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) to discuss the regulatory pathway for the development of TNX-201 (single isomer isometheptene, or IMH) for the relief of episodic tension-type headache (ETTH). ETTH is the medically-recognized term for tension headache, a common problem affecting approximately 20% of the global adult population.
Tonix Pharmaceuticals Spotlighted in Three Media Outlets in February
GlobeNewswire - Fri Feb 21, 7:20AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a development stage specialty pharmaceutical company, has been featured in TheStreet.com, Genetic Engineering & Biotechnology News and Drug Discovery News during the month of February.
Tonix Pharmaceuticals to Present at the BIO CEO Conference
GlobeNewswire - Tue Feb 04, 9:48PM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a development stage specialty pharmaceutical company, will be presenting at the 16 Annual BIO CEO & Investor Conference in New York City. Seth Lederman, M.D., president and CEO of Tonix, will deliver a corporate overview on Monday, February 10, 2014 at 4:00 PM ET.
Tonix Pharmaceuticals Announces Closing of $43.5 Million Public Offering of Common Stock
GlobeNewswire - Wed Jan 29, 10:15AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) today announced the closing of its previously announced underwritten public offering of 2,898,550 shares of its common stock. The shares were sold at the public offering price of $15.00 per share, bringing the aggregate gross proceeds from the offering to approximately $43.5 million, before deducting underwriting discounts and commissions and other offering expenses.
Tonix Pharmaceuticals Holding Corp expects USD43.5m in public offering
M2 - Mon Jan 27, 6:44AM CST
Prescription medication company Tonix Pharmaceuticals Holding Corp (NasdaqCM:TNXP) stated on Friday that it has priced its public offering of 2,898,550 shares of its common stock.
Tonix Pharmaceuticals Prices Underwritten Public Offering Raising $43.5 Million
GlobeNewswire - Fri Jan 24, 7:20AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) today announced the pricing of an underwritten public offering of 2,898,550 shares of its common stock at a price of $15.00 per share. The company has also granted to the underwriters a 45-day option to acquire an additional 434,782 shares to cover overallotments in connection with the offering. After the underwriting discount and estimated offering expenses payable by the company, the company expects to receive net proceeds of approximately $40.7 million, assuming no exercise of the overallotment option. The offering is expected to close on January 29, 2014, subject to customary closing conditions.
Tonix Pharmaceuticals Holding Corp to launch public offering of common shares
M2 - Fri Jan 24, 5:12AM CST
Pharmaceutical company Tonix Pharmaceuticals Holding Corp (NasdaqCM:TNXP) said on Thursday that it plans to offer shares of its common stock in an underwritten public offering.
Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock
GlobeNewswire - Thu Jan 23, 3:02PM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a development stage specialty pharmaceutical company, today announced that it intends to offer shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Nasdaq stocks posting largest percentage increases
AP - Tue Jan 21, 12:56PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Can the Rally in Tonix Pharmaceuticals Holding Corp. (TNXP) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 15, 8:25AM CST
Can the Rally in Tonix Pharmaceuticals Holding Corp. (TNXP) Shares Continue?
5 Stocks Rising on Unusual Volume
at The Street - Fri Dec 27, 9:13AM CST
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Tonix Pharmaceuticals Announces the Enrollment of Completers From the BESTFIT Trial Into a 12-Month Open-Label Extension Study
GlobeNewswire - Tue Dec 10, 7:40AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a development stage specialty pharmaceutical company, announced today that it is enrolling subjects into an open-label extension (OLE) study to the BESTFIT trial of TNX-102 2.8 mg sublingual tablet (SL) in fibromyalgia (FM).
Stock Price Updates, FDA 510(k) Clearances, Conference Presentation and Resignations - Research Report on Gilead, Oculus Innovative Sciences, ARCA biopharma, Arena Pharma, and Tonix Pharma
PR Newswire - Mon Dec 09, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Gilead Sciences Inc. (NASDAQ: GILD), Oculus Innovative Sciences, Inc. (NASDAQ: OCLS), ARCA biopharma, Inc. (NASDAQ: ABIO), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), and Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Tonix Pharmaceuticals to Present at the ROTH Conference
GlobeNewswire - Wed Mar 05, 7:20AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a development stage specialty pharmaceutical company, will be presenting at the 26 Annual ROTH Conference in Laguna Niguel, California. Seth Lederman, M.D., president and CEO of Tonix, will deliver a corporate overview on Tuesday, March 11, 2014 at 12:30 PM PT.
Tonix Pharmaceuticals Completes Pre-IND Meeting With FDA on TNX-201 for Episodic Tension-Type Headache: Clinical Development to Begin in 4Q 2014
GlobeNewswire - Mon Mar 03, 8:35AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a development stage specialty pharmaceutical company, today announced that it recently held a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) to discuss the regulatory pathway for the development of TNX-201 (single isomer isometheptene, or IMH) for the relief of episodic tension-type headache (ETTH). ETTH is the medically-recognized term for tension headache, a common problem affecting approximately 20% of the global adult population.
Tonix Pharmaceuticals Spotlighted in Three Media Outlets in February
GlobeNewswire - Fri Feb 21, 7:20AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a development stage specialty pharmaceutical company, has been featured in TheStreet.com, Genetic Engineering & Biotechnology News and Drug Discovery News during the month of February.
Tonix Pharmaceuticals to Present at the BIO CEO Conference
GlobeNewswire - Tue Feb 04, 9:48PM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a development stage specialty pharmaceutical company, will be presenting at the 16 Annual BIO CEO & Investor Conference in New York City. Seth Lederman, M.D., president and CEO of Tonix, will deliver a corporate overview on Monday, February 10, 2014 at 4:00 PM ET.
Tonix Pharmaceuticals Announces Closing of $43.5 Million Public Offering of Common Stock
GlobeNewswire - Wed Jan 29, 10:15AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) today announced the closing of its previously announced underwritten public offering of 2,898,550 shares of its common stock. The shares were sold at the public offering price of $15.00 per share, bringing the aggregate gross proceeds from the offering to approximately $43.5 million, before deducting underwriting discounts and commissions and other offering expenses.
Tonix Pharmaceuticals Holding Corp expects USD43.5m in public offering
M2 - Mon Jan 27, 6:44AM CST
Prescription medication company Tonix Pharmaceuticals Holding Corp (NasdaqCM:TNXP) stated on Friday that it has priced its public offering of 2,898,550 shares of its common stock.
Tonix Pharmaceuticals Prices Underwritten Public Offering Raising $43.5 Million
GlobeNewswire - Fri Jan 24, 7:20AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) today announced the pricing of an underwritten public offering of 2,898,550 shares of its common stock at a price of $15.00 per share. The company has also granted to the underwriters a 45-day option to acquire an additional 434,782 shares to cover overallotments in connection with the offering. After the underwriting discount and estimated offering expenses payable by the company, the company expects to receive net proceeds of approximately $40.7 million, assuming no exercise of the overallotment option. The offering is expected to close on January 29, 2014, subject to customary closing conditions.
Tonix Pharmaceuticals Holding Corp to launch public offering of common shares
M2 - Fri Jan 24, 5:12AM CST
Pharmaceutical company Tonix Pharmaceuticals Holding Corp (NasdaqCM:TNXP) said on Thursday that it plans to offer shares of its common stock in an underwritten public offering.
Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock
GlobeNewswire - Thu Jan 23, 3:02PM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a development stage specialty pharmaceutical company, today announced that it intends to offer shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Nasdaq stocks posting largest percentage increases
AP - Tue Jan 21, 12:56PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Can the Rally in Tonix Pharmaceuticals Holding Corp. (TNXP) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 15, 8:25AM CST
Can the Rally in Tonix Pharmaceuticals Holding Corp. (TNXP) Shares Continue?
5 Stocks Rising on Unusual Volume
at The Street - Fri Dec 27, 9:13AM CST
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Tonix Pharmaceuticals Announces the Enrollment of Completers From the BESTFIT Trial Into a 12-Month Open-Label Extension Study
GlobeNewswire - Tue Dec 10, 7:40AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a development stage specialty pharmaceutical company, announced today that it is enrolling subjects into an open-label extension (OLE) study to the BESTFIT trial of TNX-102 2.8 mg sublingual tablet (SL) in fibromyalgia (FM).
Stock Price Updates, FDA 510(k) Clearances, Conference Presentation and Resignations - Research Report on Gilead, Oculus Innovative Sciences, ARCA biopharma, Arena Pharma, and Tonix Pharma
PR Newswire - Mon Dec 09, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Gilead Sciences Inc. (NASDAQ: GILD), Oculus Innovative Sciences, Inc. (NASDAQ: OCLS), ARCA biopharma, Inc. (NASDAQ: ABIO), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), and Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
(0)
(0)Tonix Pharmaceuticals Holding Corp. (TNXP) Stock Research Links
Scroll down for more posts ▼